General Information of Drug (ID: DMV1SDA)

Drug Name
HM43239 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1/2 [1]
Cross-matching ID
PubChem CID
135390910
TTD Drug ID
DMV1SDA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [3]
Fostamatinib disodium DM3274D Thrombocytopenia 3B64 Phase 3 [4]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [5]
TAK-659 DMJH3U0 Diffuse large B-cell lymphoma 2A81 Phase 2 [6]
GS-9876 DM9Q2B6 Cutaneous lupus erythematosus EB5Z Phase 2 [7]
GS-9973 DMKWCTR Acute myeloid leukaemia 2A60 Phase 2 [8]
Cevidoplenib DM9QU5G Rheumatoid arthritis FA20 Phase 2 [9]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [10]
SKI-O-703 DMTSKXR Rheumatoid arthritis FA20 Phase 1 [7]
PRT6207 DMP5CLY Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [12]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [13]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [14]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [15]
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [16]
Pexidartinib DMS2J0Z Tenosynovial giant cell tumour 2F7B Approved [17]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [12]
Quizartinib DM8Y4JS Acute myeloid leukaemia 2A60 Approved [18]
Lestaurtinib DMQ2AIJ Acute myeloid leukaemia 2A60 Approved (orphan drug) [19]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [2]
Tyrosine-protein kinase SYK (SYK) TTOU65C KSYK_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03850574) Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Company report (Portola Pharmaceuticals)
6 J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
9 A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
10 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
11 Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
20 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.